New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
09:11 EDTBKS, CVRR, PXD, SQBG, OMI, MDCI, GLNG, AERI, NSPH, BMY, GIS, MON, IMSOn The Fly: Pre-market Movers
HIGHER: Barnes & Noble (BKS), up 7.7% after board authorizes management to separate Retail, Nook Media units... Monsanto (MON), up 5% after reporting better than expected Q3 results, raising its full year EPS outlook to the upper end of its previous guidance range and announcing a new $10B share repurchase authorization... IMS Health (IMS), up 7.7% after acquiring certain Cegedim businesses for $520M... Nanosphere (NSPH), up 16.2% after receiving 510(k) clearance for bacterial portion of Verigene EP test... Aerie Pharmaceuticals (AERI), up 37% after its trial of Roclatan achieved its primary efficacy endpoint... Medical Action (MDCI), up 94% after Owens & Minor (OMI) acquires the company for $13.80 per share in cash... Sequential Brands (SQBG), up 15% after acquiring Galaxy Brand for $100M cash, 13.75M shares... Pioneer Natural (PXD), up 2.3% after media reports that the company got U.S. permission to ship a type of light oil known as condensate... Bristol-Myers Squibb (BMY), up 2% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: General Mills (GIS), down 3.7% after Q4 earnings fall below analyst's consensus... Lindsay Corp. (LNN), down 5% after earnings miss, saying Iraq contract now more difficult to complete... Golar LNG (GLNG), down 2% after 11M share offering priced at $54 per share... CVR Refining (CVRR), down 7% after 6M share secondary offering of common units price at $26.07.
News For BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS From The Last 14 Days
Check below for free stories on BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 29, 2014
09:29 EDTCVRRCVR says four employees injured in fire at Coffeyville's isomerization unit
Subscribe for More Information
07:09 EDTBMYBristol-Myers, Pfizer granted EU approval for Eliquis for treatment of DVT, PE
Subscribe for More Information
July 28, 2014
17:19 EDTOMIOwens & Minor names James Bierman next CEO
Owens & Minor announced that its Board of Directors has named President & COO James L. Bierman, 61, to serve as President & CEO and appointed him as a director of the company, effective September 1, Craig R. Smith currently Chairman & CEO, will continue to serve the company in the role of Executive Chairman.
17:16 EDTOMIOwens & Minor reports Q2 EPS 40c, consensus 46c
Reports Q2 revenue $2.31B, consensus $2.27B.
July 25, 2014
07:27 EDTBMYEMA recommends expanded indication for Baraclude
Subscribe for More Information
06:00 EDTBMYBristol-Myers implied volatility of 17 at lower end of index mean range
Subscribe for More Information
July 24, 2014
17:05 EDTCVRRCarl Icahn confirms 70% stake in CVR Refining following offering
Subscribe for More Information
11:22 EDTBMYBristol-Myers says considering different sizes of deal opportunities
Subscribe for More Information
10:57 EDTBMYBristol-Myers says M&A would have to be good strategic fit
Subscribe for More Information
10:48 EDTBMYBristol-Myers says guidance assumes R&D credit will be extended
Says Reyataz seeing increased competitive pressure. Says business development a top priority for capital allocation. Comments made on the Q2 earnings conference call.
08:28 EDTBMYBristol-Myers management to meet with JPMorgan
Subscribe for More Information
07:33 EDTAERIAerie receives NOL for Rhopressa Phase 3 registration trial
Aerie Pharmaceuticals announced that it has received a No Objection Letter from Health Canada to conduct a Phase 3 registration trial of Rhopressa. The study, named “Rocket 3,” is designed to evaluate safety and tolerability of Rhopressa in patients over 12 months and is part of a broad Phase 3 program being conducted by Aerie. The company recently announced the commencement of two Phase 3 trials in the U.S., “Rocket 1” and “Rocket 2,” which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa. The company said, " Pending progress of the program and regulatory approvals, Aerie intends to commercialize Rhopressa in North American markets with its own sales force and will seek commercialization partners in other key territories, including Europe and Japan. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030."
07:32 EDTBMYBristol-Myers reaffirms 2014 EPS outlook $1.70-$1.80, consensus $1.77
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q2 EPS 48c, consensus 44c
Reports Q2 revenue $ $3.89B, consensus $3.85B.
07:15 EDTIMSIMS Health sees FY14 revenue growth 5%-6%, consensus $2.68B
Subscribe for More Information
07:03 EDTIMSIMS Health reports Q2 adjusted EPS 39, consensus 37c
Subscribe for More Information
05:26 EDTBMYBristol-Myers, Ono Pharmaceutical announces strategic collaboration in Japan
Bristol-Myers Squibb and Ono Pharmaceutical have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. As part of the agreement, Bristol-Myers Squibb and Ono will jointly develop and commercialize Opdivo and Yervoy across a broad range of tumor types. Bristol-Myers Squibb and Ono will jointly pursue development of monotherapy and combination regimens, with Opdivo as the foundational therapy in Japan, South Korea and Taiwan, and leverage global clinical trials by including patients from the three countries.
July 23, 2014
15:30 EDTBMYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
15:10 EDTBMYBristol-Myers technical comments before earnings
Subscribe for More Information
July 21, 2014
06:43 EDTBMYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use